Does the use of postoperative low-molecular-weight heparin in patients with lung cancer increase tube drainage?

Eşme, Hıdır; Can, Atilla; Şehitoğulları, Abidin

doi:10.1016/j.asjsur.2019.03.008

Cited by 3 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26,28,29,31,38,43 Prophylaxis with LMWH was performed in the studies of Daddi, Attaran, Song, Mantziari, Christensen, Song, Pannucci, and Esme. 30,33,35,36,40,41,42,44 Dentali, Agzarian, and Alai 37,47 compared prophylaxis of LMWH or heparin in patients receiving lung surgery; Tanaka 46 compared prophylaxis of an IPC or enoxaparin in patients who underwent esophagectomy for esophageal cancer;…”

Section: Discussionmentioning

confidence: 99%

“…A prophylaxis regimen period of 3 days after the surgery was described be Esme. 44 In the study of Mantziari, 36 pharmacological prophylaxis for VTE started the day before surgery and continued after discharge from 7 to 28 days. In the study of Song, 35 the prophylaxis was conducted from 6 h after surgery and stopped on the 7th postoperative day.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The venous thromboembolism prophylaxis in patients receiving thoracic surgery: A systematic review

Wang

Ding

Yang

2020

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Objectives: Venous thromboembolism (VTE) is a significant and preventable cause of mortality and morbidity in thoracic surgery. It usually deep venous thromboembolism (DVT) and pulmonary thromboembolism (PE). We conducted this article to perform a systematic review on prophylaxis of perioperative VTE in patients undergoing thoracic surgery especially lung surgery and esophageal surgery and to identify potential areas for future research. Methods:The systematic review we conducted included studies of patients undergoing thoracic surgery especially lung surgery and esophageal surgery Results:The study identified 2621 references. Finally, 22 trials with a total of 9072 patients were included. Only six studies declared that they continued a follow-up after the discharge of the patients. (range: 1-3 months); three studies reported on major bleeding events as an outcome measure, and the incidence varied from 0.8% to 1.6%.Total 346 VTEs occurred, and the overall mean risk of VTE was estimated at 3.8% (range: 0.77-27%). Conclusions:The evidence for using thromboprophylaxis in thoracic surgery is limited and controversial, predominantly based on clinical consensus. Future research is needed to focus on identifying risk of VTE and providing sufficient evidence with high quality to support clinical strategies concerning the prophylaxis for VTE.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The venous thromboembolism prophylaxis in patients receiving thoracic surgery: A systematic review

Wang

Ding

Yang

2020

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

show abstract

Incidence of venous thromboembolism and bleeding after pulmonary lobectomy: evaluating the timing for thromboprophylaxis

Smith

Raíces

Diego

et al. 2020

J Thromb Thrombolysis

View full text Add to dashboard Cite

Safety profile of preoperative administration of low-molecular-weight heparin on minimally invasive lung cancer surgery: a randomized controlled trial

Alai

Zhuo

et al. 2021

BMC Surg

View full text Add to dashboard Cite

Background Venous thromboembolism remains a common but preventable complication for cancerous lung surgical patients. Current guidelines recommend thromboprophylaxis for lung patients at high risk of thrombosis, while a consensus about specific administration time is not reached. This study was designed to investigate the safety profile of preoperative administration of low-molecular-weight-heparin (LMWH) for lung cancer patients. Methods From July 2017 to June 2018, patients prepared to undergo lung cancer surgery were randomly divided into the preoperative LMWH-administration group (PRL) for 4000 IU per day and the postoperative LMWH-administration group (POL) with same dosage, all the patients received thromboprophylaxis until discharge. Baseline characteristics including demographics and preoperative coagulation parameters were analyzed, while the endpoints included postoperative coagulation parameters, postoperative drainage data, hematologic data, intraoperative bleeding volume and reoperation rate. Results A total of 246 patients were collected in this RCT, 34 patients were excluded according to exclusion criterion, 101 patients were assigned to PRL group and 111 patients belonged to POL group for analysis finally. The baseline characteristic and preoperative coagulation parameters were all comparable except the PRL group cost more operation time (p = 0.008) and preoperative administration duration was significantly longer (p < 0.001). The endpoints including postoperative day 1 coagulation parameters, mean and total drainage volume, drainage duration, intraoperative bleeding volume and reoperation rate were all similar between the two groups. Moreover, coagulation parameters for postoperative day 3 between the two groups demonstrated no difference. Conclusion Preoperative administration of low-molecular-weight-heparin demonstrated safety and feasibility for lung cancer patients intended to receive minimally invasive surgery. Trial registration: ChiCTR2000040547 (www.chictr.org.cn), 2020/12/1, retrospectively registered.

show abstract

Does the use of postoperative low-molecular-weight heparin in patients with lung cancer increase tube drainage?

Cited by 3 publications

References 13 publications

The venous thromboembolism prophylaxis in patients receiving thoracic surgery: A systematic review

The venous thromboembolism prophylaxis in patients receiving thoracic surgery: A systematic review

Incidence of venous thromboembolism and bleeding after pulmonary lobectomy: evaluating the timing for thromboprophylaxis

Safety profile of preoperative administration of low-molecular-weight heparin on minimally invasive lung cancer surgery: a randomized controlled trial

Contact Info

Product

Resources

About